Development of autogenous vaccines for the control of amoebic gill disease in farmed Atlantic salmon

该项目汇集了来自斯特林大学水产研究所、里奇韦生物制品有限公司、一家专门生产自体疫苗的中小型企业，利用苏格兰最大的鲑鱼生产商Marine Harvest的水产养殖生产知识，开发和现场测试用于控制养殖鲑鱼阿米巴鳃病（AGD）的疫苗。其目标是为年龄、性别和疾病研制针对农场的疫苗，尽管迫切需要这种疾病，但目前尚无疫苗。这种疾病在2011年首次给英国鲑鱼养殖业造成重大问题，迄今为止给英国和爱尔兰的产业造成了5000万英镑的损失。基于农场特异性种子分离株的自体疫苗可以根据兽药局控制的特定法规生产。这种疫苗可以在没有任何完全许可的疫苗可用于特定病原体的情况下制造和供应。面对年龄、性别和多元性疾病等新出现的疾病威胁，这些产品有可能得到迅速开发和部署。

This project brings together fish health and vaccinology expertise from the University of Stirling's Institute of Aquaculture, Ridgeway Biologicals Ltd., an SME specialising in the production of autogenous vaccines, and aquaculture production knowledge from Marine Harvest, Scotland's biggest salmon producer, to develop and field test vaccines for the control of Amoebic Gill Disease (AGD) in farmed salmon. The objective is to develop farm-specific vaccines for AGD, a disease for which there is no vaccine despite an urgent need. This disease first caused major problems for the UK salmon aquaculture industry in 2011, costing UK and Irish industries £50 million to date. Autogenous vaccines, based on farm-specific seed isolates, can be produced under specific regulations, controlled by the Veterinary Medicines Directorate. Such vaccines can be manufactured and supplied in the absence of any fully licensed vaccine being available for a specific pathogen. Such products have the potential to be developed and deployed rapidly in the face of emerging disease threats such as AGD.